[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"829b11a8-2149-49a1-8445-bba09c622fc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06739395","created_at":"2025-02-26T09:10:09.582Z","updated_at":"2025-02-26T09:10:09.582Z","phase":"Phase 2","brief_title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","source_id_and_acronym":"NCT06739395","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-12-18"},{"id":"7c689d51-0e44-4011-9164-a6ec2c89625e","acronym":"COMBI-i","url":"https://clinicaltrials.gov/study/NCT02967692","created_at":"2021-01-17T17:17:14.303Z","updated_at":"2024-07-02T16:34:25.889Z","phase":"Phase 3","brief_title":"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma","source_id_and_acronym":"NCT02967692 - COMBI-i","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • BRAF V600","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 569","initiation":"Initiation: 02/17/2017","start_date":" 02/17/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2024-06-14"},{"id":"1f12d403-2fb1-4336-8060-02027bae83cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04294160","created_at":"2021-01-18T20:50:10.771Z","updated_at":"2024-07-02T16:34:27.442Z","phase":"Phase 1","brief_title":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","source_id_and_acronym":"NCT04294160","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • naporafenib (ERAS-254) • batoprotafib (TNO155) • rineterkib (LTT462)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 10/11/2024","primary_completion_date":" 10/11/2024","study_txt":" Completion: 10/11/2024","study_completion_date":" 10/11/2024","last_update_posted":"2024-06-11"},{"id":"cfc2985f-51c4-4ab9-8232-962b73ff7481","acronym":"NCI-2013-02103","url":"https://clinicaltrials.gov/study/NCT01989585","created_at":"2021-01-18T09:04:22.279Z","updated_at":"2024-07-02T16:35:03.325Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","source_id_and_acronym":"NCT01989585 - NCI-2013-02103","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • BCL2","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K","tags":["PTEN • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/24/2014","start_date":" 03/24/2014","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-16"},{"id":"823badf9-4b8a-4d3d-963d-74998c35cebb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03091257","created_at":"2021-01-18T15:13:47.235Z","updated_at":"2025-02-25T15:53:42.148Z","phase":"Phase 1","brief_title":"A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03091257","lead_sponsor":"Massachusetts General Hospital","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/21/2017","start_date":" 06/21/2017","primary_txt":" Primary completion: 09/15/2024","primary_completion_date":" 09/15/2024","study_txt":" Completion: 09/15/2024","study_completion_date":" 09/15/2024","last_update_posted":"2024-04-16"},{"id":"bd4d0e13-8987-4f75-b586-db0b96b6ac26","acronym":"","url":"https://clinicaltrials.gov/study/NCT06362694","created_at":"2024-04-12T14:46:15.420Z","updated_at":"2024-07-02T16:35:09.932Z","phase":"Phase 2","brief_title":"Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy","source_id_and_acronym":"NCT06362694","lead_sponsor":"Saint Petersburg State University, Russia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/25/2024","start_date":" 03/25/2024","primary_txt":" Primary completion: 03/25/2026","primary_completion_date":" 03/25/2026","study_txt":" Completion: 06/25/2026","study_completion_date":" 06/25/2026","last_update_posted":"2024-04-12"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"92b543b8-0666-45b8-8525-786af02d2693","acronym":"","url":"https://clinicaltrials.gov/study/NCT04418167","created_at":"2021-01-18T21:17:40.725Z","updated_at":"2024-07-02T16:35:20.996Z","phase":"Phase 1","brief_title":"JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations","source_id_and_acronym":"NCT04418167","lead_sponsor":"JS InnoPharm, LLC","biomarkers":" MAP2K1 • NF1 • RASA1","pipe":" | ","alterations":" BRAF V600E • BRAF V600K","tags":["MAP2K1 • NF1 • RASA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tafinlar (dabrafenib) • JSI-1187"],"overall_status":"Suspended","enrollment":" Enrollment 71","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/17/2024","study_completion_date":" 12/17/2024","last_update_posted":"2024-02-02"},{"id":"58b26f64-7b26-4c99-ba89-84483413fd67","acronym":"","url":"https://clinicaltrials.gov/study/NCT02367859","created_at":"2021-01-18T11:16:38.843Z","updated_at":"2025-02-25T15:42:16.020Z","phase":"Phase 2","brief_title":"Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma","source_id_and_acronym":"NCT02367859","lead_sponsor":"Stanford University","biomarkers":" ALK • RAF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["ALK • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 11/05/2018","primary_completion_date":" 11/05/2018","study_txt":" Completion: 06/26/2019","study_completion_date":" 06/26/2019","last_update_posted":"2024-01-30"},{"id":"40ebe0f1-7223-4382-ac12-72f3985d9796","acronym":"I-FIRST","url":"https://clinicaltrials.gov/study/NCT05182931","created_at":"2022-01-10T14:58:20.818Z","updated_at":"2024-07-02T16:35:31.101Z","phase":"Phase 2","brief_title":"A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)","source_id_and_acronym":"NCT05182931 - I-FIRST","lead_sponsor":"Olivia Newton-John Cancer Research Institute","biomarkers":" NRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-10-31"},{"id":"eeb73878-2f88-40c3-b001-91ad549f256b","acronym":"TraMel-WT","url":"https://clinicaltrials.gov/study/NCT04059224","created_at":"2021-01-18T19:53:47.469Z","updated_at":"2024-07-02T16:35:35.732Z","phase":"Phase 2","brief_title":"TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma","source_id_and_acronym":"NCT04059224 - TraMel-WT","lead_sponsor":"Universitair Ziekenhuis Brussel","biomarkers":" KIT","pipe":" | ","alterations":" BRAF mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 01/28/2019","start_date":" 01/28/2019","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-09-26"},{"id":"470938e4-0678-4e31-a0e5-6829ffd1415d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05299580","created_at":"2022-03-29T13:52:57.410Z","updated_at":"2024-07-02T16:35:36.936Z","phase":"Phase 2","brief_title":"\"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)\"","source_id_and_acronym":"NCT05299580","lead_sponsor":"Fondazione Melanoma Onlus","biomarkers":" PD-L1","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 03/30/2023","primary_completion_date":" 03/30/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2023-09-14"},{"id":"fb8dc3ab-b4a9-4b4d-aae6-7233509f61b6","acronym":"Neo Combi","url":"https://clinicaltrials.gov/study/NCT01972347","created_at":"2021-03-01T20:52:35.949Z","updated_at":"2024-07-02T16:35:38.660Z","phase":"Phase 2","brief_title":"Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma","source_id_and_acronym":"NCT01972347 - Neo Combi","lead_sponsor":"Melanoma Institute Australia","biomarkers":" EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 05/04/2017","primary_completion_date":" 05/04/2017","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-08-30"},{"id":"53537bf3-eae7-42ad-947c-fe82b3ec3eae","acronym":"ERRITI","url":"https://clinicaltrials.gov/study/NCT04619316","created_at":"2021-01-19T20:34:09.715Z","updated_at":"2024-07-02T16:35:45.180Z","phase":"Phase 2","brief_title":"Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition","source_id_and_acronym":"NCT04619316 - ERRITI","lead_sponsor":"University Hospital, Essen","biomarkers":" TG","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-06-22"},{"id":"8790b5b4-a08c-451b-a3e9-b8bd7f87117b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04527549","created_at":"2021-01-18T21:40:53.974Z","updated_at":"2024-07-02T16:35:45.270Z","phase":"Phase 2","brief_title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","source_id_and_acronym":"NCT04527549","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" IL2","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2023-06-22"},{"id":"7b600c66-24c1-482b-864d-44446e04f486","acronym":"KEYNOTE-022","url":"https://clinicaltrials.gov/study/NCT02130466","created_at":"2021-01-17T17:23:06.266Z","updated_at":"2025-02-25T15:41:35.081Z","phase":"Phase 1/2","brief_title":"A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)","source_id_and_acronym":"NCT02130466 - KEYNOTE-022","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" BRAF V600","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Completed","enrollment":" Enrollment 184","initiation":"Initiation: 05/29/2014","start_date":" 05/29/2014","primary_txt":" Primary completion: 07/14/2021","primary_completion_date":" 07/14/2021","study_txt":" Completion: 07/14/2021","study_completion_date":" 07/14/2021","last_update_posted":"2022-08-01"},{"id":"ce9c2f83-6e20-41ea-8a52-3b7f9484085f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03668431","created_at":"2021-01-18T17:59:52.829Z","updated_at":"2025-02-25T15:43:12.003Z","phase":"Phase 2","brief_title":"Dabrafenib + Trametinib + PDR001 In Colorectal Cancer","source_id_and_acronym":"NCT03668431","lead_sponsor":"Massachusetts General Hospital","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • BRAF V600 • KRAS wild-type • NRAS wild-type","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • BRAF V600 • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • spartalizumab (PDR001)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-06-27"},{"id":"589fc224-1f44-451f-847a-4d0ffa6361d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02257424","created_at":"2021-01-18T10:36:10.936Z","updated_at":"2024-07-02T16:36:18.245Z","phase":"Phase 1/2","brief_title":"Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma","source_id_and_acronym":"NCT02257424","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" IL2","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D • BRAF V600E + BRAF V600K","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2022-01-20"},{"id":"7d05540a-250d-4ae8-8938-40bcf84b4618","acronym":"","url":"https://clinicaltrials.gov/study/NCT01750918","created_at":"2021-01-17T17:23:33.466Z","updated_at":"2024-07-02T16:36:22.123Z","phase":"Phase 1/2","brief_title":"BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)","source_id_and_acronym":"NCT01750918","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • 5-fluorouracil • Vectibix (panitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 166","initiation":"Initiation: 12/19/2012","start_date":" 12/19/2012","primary_txt":" Primary completion: 06/18/2020","primary_completion_date":" 06/18/2020","study_txt":" Completion: 06/18/2020","study_completion_date":" 06/18/2020","last_update_posted":"2021-10-29"},{"id":"e5b2fa7d-d093-4b38-afac-9476bd5a7056","acronym":"MERAIODE","url":"https://clinicaltrials.gov/study/NCT03244956","created_at":"2021-01-18T16:02:03.431Z","updated_at":"2024-07-02T16:36:23.819Z","phase":"Phase 2","brief_title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03244956 - MERAIODE","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • HRAS mutation • BRAF K601E • BRAF K601","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • HRAS mutation • BRAF K601E • BRAF K601"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-09-28"},{"id":"83385b77-9ea5-4d67-9e51-7f9e43d6472e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03794297","created_at":"2021-01-18T18:45:38.324Z","updated_at":"2024-07-02T16:36:33.171Z","phase":"Phase 2","brief_title":"Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations","source_id_and_acronym":"NCT03794297","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • CRP","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["ER • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 02/18/2021","primary_completion_date":" 02/18/2021","study_txt":" Completion: 02/18/2021","study_completion_date":" 02/18/2021","last_update_posted":"2021-03-17"},{"id":"beafe807-5a78-4bd5-ba5e-40d252bfd50e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04554680","created_at":"2021-01-18T21:46:28.506Z","updated_at":"2024-07-02T16:36:33.733Z","phase":"Phase 2","brief_title":"Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF \u0026 MEK Blockade for Re-differentiation Therapy","source_id_and_acronym":"NCT04554680","lead_sponsor":"National University Hospital, Singapore","biomarkers":" TG","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2021-03-05"},{"id":"3d1b2e02-0b22-495b-9eec-788ad524f8cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01726738","created_at":"2021-01-18T07:32:30.279Z","updated_at":"2025-02-25T13:10:32.240Z","phase":"Phase 2","brief_title":"LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations","source_id_and_acronym":"NCT01726738","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PTEN • MAP3K8","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600 • BRAF V600K","tags":["PTEN • MAP3K8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 04/04/2013","start_date":" 04/04/2013","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 09/17/2020","study_completion_date":" 09/17/2020","last_update_posted":"2020-11-23"}]